2010
DOI: 10.1007/s00535-009-0183-y
|View full text |Cite
|
Sign up to set email alerts
|

Protein profiles of peripheral blood mononuclear cells are useful for differential diagnosis of ulcerative colitis and Crohn’s disease

Abstract: PBMC protein profiles are useful for the discrimination of UC from CD. The profiles could be a potent biomarker for the differential diagnosis of these diseases. Further investigation of the proteins which contributed to the discrimination could promote elucidation of the pathophysiology of UC and CD.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
41
0

Year Published

2011
2011
2022
2022

Publication Types

Select...
6
2

Relationship

4
4

Authors

Journals

citations
Cited by 48 publications
(41 citation statements)
references
References 38 publications
0
41
0
Order By: Relevance
“…An existing example is the Brignola score which predicts relapse risk in asymptomatic Crohn's patients by measures erythrocyte sedimentation rate, white blood cell count, hemoglobin, albumin, alpha 2globulin, serum iron, Creactive protein, alpha 1glycoprotein, and alpha 2antitrypsin [41] . This has been hinted at in several IBD proteomic studies which differentiated UC and CD using protein profiles rather than discrete markers [22,24] . The role of multiple biomarkers is highlighted by OVA1, the first Food and Drug Administration approved proteomic panel of biomarkers, consisting of 5 markers as a multivariate index assay.…”
Section: Fecal Calprotectinmentioning
confidence: 99%
See 2 more Smart Citations
“…An existing example is the Brignola score which predicts relapse risk in asymptomatic Crohn's patients by measures erythrocyte sedimentation rate, white blood cell count, hemoglobin, albumin, alpha 2globulin, serum iron, Creactive protein, alpha 1glycoprotein, and alpha 2antitrypsin [41] . This has been hinted at in several IBD proteomic studies which differentiated UC and CD using protein profiles rather than discrete markers [22,24] . The role of multiple biomarkers is highlighted by OVA1, the first Food and Drug Administration approved proteomic panel of biomarkers, consisting of 5 markers as a multivariate index assay.…”
Section: Fecal Calprotectinmentioning
confidence: 99%
“…Healthy controls: 30 Kanmura et al [23] Blood CD: 22 SELDI-TOF Plasma concentrations of HNP1, 2 and 3 were significantly higher in active UC compared to inactive UC, CD and control patients UC: 48 Colorectal Cancer: 5 Infectious colitis: 6 Healthy controls: 13 Hatsugai et al [24] Blood CD: 13 2-DE Multivariate analysis of peripheral blood mononuclear cells protein profile 58 protein) allowed for accurate discrimination between UC and CD UC: 17 MALDI-TOF Healthy controls: 17 Nanni et al [25] Blood…”
Section: Uc: 30 Inflammatory Control: 30mentioning
confidence: 99%
See 1 more Smart Citation
“…Metabolic status was determined using criteria adapted from that originally proposed by Karelis et al [276] in order to account for sex--specific differences and medication. An individual was considered identified using Variables of Importance in Projection (VIP) > 1 [277]. FAs meeting our VIP cut--off were then individually assessed between the three groups using a non--parametric ANOVA Kruskal--Wallis test (P < 0.05).…”
Section: Classification Of Groups Thirty Participants Were Classifiementioning
confidence: 99%
“…Recently, there have been great advances in proteomics, the science dealing with the comprehensive analysis of protein expression. Proteomics have been applied to search of biomarkers in various diseases (8)(9)(10). In this paper, we introduced proteomic studies which explored biomarkers for UC by analyzing proteins in various clinical samples such as sera, peripheral blood mononuclear cells (PBMCs) and colonic mucosa.…”
Section: Introductionmentioning
confidence: 99%